Novartis AG (LTS:0K9E)
$ 104.7 0 (0%) Market Cap: 209.81 Bil Enterprise Value: 227.95 Bil PE Ratio: 12.53 PB Ratio: 5.07 GF Score: 80/100

Novartis AG Mayzent FDA Approval Investor Call Transcript

Mar 27, 2019 / 11:45AM GMT
Operator

Good morning and good afternoon, and welcome to the Mayzent FDA Approval Conference Call and Live Audio Webcast. (Operator Instructions) The conference is being recorded. (Operator Instructions)

With that, I would like to hand over to Mr. Pierre-Michel Bringer, Investor Relations Officer. Please go ahead, sir.

Pierre;Michel Bringer
Novartis AG - Former IR Officer

Okay, thank you. Good morning, good afternoon, everybody. This is Pierre-Michel from Investor Relations. Thank you for joining us today to discuss the approval of Mayzent, an important addition to our MS franchise and particularly important for people with MS.

Joining me today are Paul Hudson, CEO of Novartis Pharmaceuticals; Danny Bar-Zohar, Development Head, Neuroscience unit. Both Paul and Danny will make some opening comments, following which we'll take your questions. Note that we plan to finish around 1:30, which is in about 45 minutes from now.

Before turning the call over to Paul, I would like to remind you that the information presented today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot